Research & Reports

A black baby in the U.S. is more than twice as likely to die before its first birthday as a white baby. In addition to the medical care and access a woman and baby receive, these poor outcomes are also driven by social determinants of health—non-clinical factors such as social, educational, environmental, and economic opportunities that affect a woman’s overall health and wellbeing. This multi-faceted challenge requires a multi-faceted approach.

The shortlist for Ethical Corporation's 9th Annual Responsible Business Awards has been announced. The winners will be revealed and celebrated at a glamorous Awards Dinner ceremony on 9th October in central London

Sustainable development is core to our business strategy. We balance a daily operational focus of sourcing wood, identifying productivity improvements and fulfilling customer orders, with a longterm view for growth in core markets and expansion through investment in new markets, innovative equipment and groundbreaking technology.

Recently winning silver at the 13th annual Singapore Corporate Awards in the Big Cap category, our 2017 Annual Report is the first on Olam’s journey to develop a new model of reporting that provides insight into how we create value for multiple stakeholders over the long-term.

Fifteen leading luxury companies today launched a new report outlining opportunities and recommendations for the luxury sector to address the global challenges posed by climate change and biodiversity loss, new technologies and automation, and rising economic inequality.

UNEP FI's newly released report "Navigating a New Climate" outlines findings from 16 banks piloting the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) and the estimated impact of climate change on their corporate lending portfolios. The report prominently features the use of MAPS as a geospatial mapping tool for physical risk assessment.

The America’s Pledge report provides a ten-part opportunity agenda for bottom-up climate policies and programs to help deliver America’s Pledge under the Paris Agreement on climate change.

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) to extend its drug donation for Egaten® (triclabendazole) until 2022. Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines.

As with other organizations that have chosen to make sustainability part of their strategic imperative, sustainability at NRG means driving business results, reducing risk and enhancing the company’s brand value. Sustainable Business lies at the core of our five-pillar strategy because it encompasses initiatives that embed sustainability in the organization.

We have long known that our Living Progress plan is the right thing for a responsible company to do. But we now have increasing evidence that our sustainability credentials contribute to our business objectives and deliver value to our shareholders. This trend is reflected in the burgeoning growth of the sustainability investment sector.